JO3061B1 - صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها - Google Patents

صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها

Info

Publication number
JO3061B1
JO3061B1 JOP/2010/0433A JOP20100433A JO3061B1 JO 3061 B1 JO3061 B1 JO 3061B1 JO P20100433 A JOP20100433 A JO P20100433A JO 3061 B1 JO3061 B1 JO 3061B1
Authority
JO
Jordan
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
JOP/2010/0433A
Other languages
English (en)
Inventor
Prasad Koteswara Kapa
Mckenna Joseph
Slade Joel
Berghausen Joerg
Wu Raeann
Du Zhengming
Stowasser Frank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43983750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3061(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3061B1 publication Critical patent/JO3061B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

تقدم التقنية الحالية صور بلورية لامائية ومائية جديدة 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا، بولى مورفات لابلورية وبلورية لامائية لملح حمض احادى فوسفوريك منها ، متضمناً ثنائى الهيدرات منها . تتضمن التقنية الحالية أكثر من ذلك طرق لتحضير الصور المتباينة ، التركيبات المحتوية عليها ، وطرق المعالجة الموظفة لها.
JOP/2010/0433A 2009-12-07 2010-12-05 صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها JO3061B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26715509P 2009-12-07 2009-12-07

Publications (1)

Publication Number Publication Date
JO3061B1 true JO3061B1 (ar) 2017-03-15

Family

ID=43983750

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0433A JO3061B1 (ar) 2009-12-07 2010-12-05 صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها

Country Status (32)

Country Link
US (1) US9067896B2 (ar)
EP (1) EP2509963B1 (ar)
JP (2) JP5714024B2 (ar)
KR (1) KR101787784B1 (ar)
CN (5) CN111100078A (ar)
AR (2) AR079257A1 (ar)
AU (1) AU2010328391B2 (ar)
CA (1) CA2781431C (ar)
CL (1) CL2012001480A1 (ar)
DK (1) DK2509963T3 (ar)
EC (1) ECSP12012026A (ar)
ES (1) ES2562462T3 (ar)
GT (1) GT201200181A (ar)
HK (1) HK1171016A1 (ar)
HR (1) HRP20160126T1 (ar)
HU (1) HUE026983T2 (ar)
IL (1) IL220012B (ar)
JO (1) JO3061B1 (ar)
MA (1) MA33849B1 (ar)
MX (1) MX2012006562A (ar)
MY (1) MY158333A (ar)
NZ (3) NZ624315A (ar)
PE (1) PE20121499A1 (ar)
PH (1) PH12014502593A1 (ar)
PL (1) PL2509963T3 (ar)
RU (1) RU2572848C2 (ar)
SG (1) SG10201408063SA (ar)
SI (1) SI2509963T1 (ar)
TN (1) TN2012000263A1 (ar)
TW (1) TWI526440B (ar)
WO (1) WO2011071821A1 (ar)
ZA (1) ZA201203612B (ar)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP6190871B2 (ja) 2012-03-30 2017-08-30 ノバルティス アーゲー 低リン血症性障害の処置に使用するためのfgfr阻害剤
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
EA036160B1 (ru) 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
PT3057943T (pt) * 2013-10-18 2018-07-24 Eisai R&D Man Co Ltd Inibidores de fgfr4 pirimidina
AR098716A1 (es) * 2013-12-13 2016-06-08 Novartis Ag Formas de dosificación farmacéuticas
CN106660997B (zh) 2014-08-18 2019-05-21 卫材R&D管理有限公司 单环吡啶衍生物的盐及其晶体
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
AU2016248056B2 (en) 2015-04-14 2020-07-23 Eisai R&D Management Co., Ltd. Crystalline FGFR4 inhibitor compound and uses thereof
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2,4,5‑三取代嘧啶类化合物及其制备方法和用途
WO2016189472A1 (en) 2015-05-28 2016-12-01 Novartis Ag Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor
EP3454898B1 (en) 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
JP6667014B2 (ja) * 2016-05-20 2020-03-18 浙江海正薬業股▲ふん▼有限公司Zhejiang Hisun Pharmaceutical CO.,LTD. ピリミジン誘導体、その調製方法および医療での使用
EP3503923B1 (en) * 2016-08-23 2023-10-04 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
WO2019085893A1 (zh) * 2017-11-01 2019-05-09 广东众生药业股份有限公司 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
US11583602B2 (en) 2021-06-23 2023-02-21 Kimtron, Inc. System and method for ultra-close proximity irradiation of rotating biomass
WO2023174400A1 (zh) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101242843A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
EP1957516B1 (en) * 2005-11-08 2016-03-09 Choongwae Pharma Corporation Alfa-helix mimetics and method relating to the treatment of cancer stem cells
SMP200800041B (it) * 2005-12-21 2009-07-14 Novartis Ag Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
MX2010011959A (es) * 2008-04-29 2010-11-30 Novartis Ag Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas

Also Published As

Publication number Publication date
NZ600070A (en) 2014-06-27
CA2781431A1 (en) 2011-06-16
RU2012128351A (ru) 2014-01-20
CN111100077A (zh) 2020-05-05
CA2781431C (en) 2017-10-31
ES2562462T3 (es) 2016-03-04
US20120245182A1 (en) 2012-09-27
NZ700778A (en) 2015-04-24
IL220012B (en) 2018-02-28
AR114946A2 (es) 2020-11-11
IL220012A0 (en) 2012-07-31
MA33849B1 (ar) 2012-12-03
WO2011071821A1 (en) 2011-06-16
RU2572848C2 (ru) 2016-01-20
TWI526440B (zh) 2016-03-21
MY158333A (en) 2016-09-30
JP2015107996A (ja) 2015-06-11
PL2509963T3 (pl) 2016-05-31
CN102639510A (zh) 2012-08-15
NZ624315A (en) 2014-11-28
SG10201408063SA (en) 2015-01-29
BR112012013784A8 (pt) 2017-12-26
CN105061332A (zh) 2015-11-18
HK1171016A1 (zh) 2013-03-15
HUE026983T2 (en) 2016-08-29
CN111100078A (zh) 2020-05-05
ZA201203612B (en) 2013-01-30
EP2509963B1 (en) 2015-11-25
KR20130028045A (ko) 2013-03-18
PE20121499A1 (es) 2012-11-15
KR101787784B1 (ko) 2017-10-18
JP2013512956A (ja) 2013-04-18
BR112012013784A2 (pt) 2016-05-03
PH12014502593A1 (en) 2015-09-21
AR079257A1 (es) 2012-01-04
SI2509963T1 (sl) 2016-05-31
DK2509963T3 (en) 2016-02-29
AU2010328391A1 (en) 2012-06-07
AU2010328391B2 (en) 2014-07-03
HRP20160126T1 (hr) 2016-03-25
TW201144297A (en) 2011-12-16
CN111269186A (zh) 2020-06-12
MX2012006562A (es) 2012-07-04
JP6019142B2 (ja) 2016-11-02
GT201200181A (es) 2013-12-03
ECSP12012026A (es) 2012-08-31
EP2509963A1 (en) 2012-10-17
TN2012000263A1 (en) 2013-12-12
JP5714024B2 (ja) 2015-05-07
US9067896B2 (en) 2015-06-30
CL2012001480A1 (es) 2014-09-05

Similar Documents

Publication Publication Date Title
TN2012000263A1 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MX347257B (es) Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
ZA200804198B (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MY160785A (en) Manufacturing process for pyrimidine derivatives
TW200635905A (en) Processes for producing 4-aminoquinazolines
WO2011104723A3 (en) Acid addition salts of ivabradine and preparation method thereof
MX2010001938A (es) Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina.
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
IN2012DN01292A (ar)
EA201071425A1 (ru) Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
WO2010035284A3 (en) An improved process for the preparation of rosuvastatin calcium
MY157492A (en) Pharmaceutical composition 271
ZA200800138B (en) Process for the preparation of crystalline perindopril
UA108979C2 (uk) Застосування тетоміласту при лікуванні фіброзу або легеневої емфіземи
CY1117185T1 (el) Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων
TW200626578A (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
MX2010002300A (es) Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
MY162757A (en) New Crystalline Forms of 4,4’-[4-Fluoro-7-({4-[4-(3-Fluoro-2-Methylphenyl) Butoxy] Phenyl}Ethynyl)-2-Methyl-1H-Indole-1, 3-Diyl] Dibutanoic Acid
GR20110100398A (el) Μεθοδος για την παρασκευη αλατος του 3-(ν-μεθυλ-ν-πεντυλ) αμινο-1-υδροξυπροπανιο-1,1-διφωσφονικου οξεος, αλατος ή παραγωγων αυτου
TH138420A (th) รูปผลึกของ 3-(2,6-ไดคลอโร-3,5-ไดเมธอกซี-เฟนิล)-1-{6-[4-(4-เอธิล-พิเพอราซิน-1-อิล)-เฟนิลอะมิโน]-พิริมิดิน-4-อิล}-1-เมธิล-ยูเรีย และเกลือของสิ่งนั้น
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts